CROSSROADS STRATEGIES, LLC for LILLY USA, LLC
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
FDA's accelerated approval pathway; insulin price cap; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| MATHEW LAPINSKI | — |
| BEN LEE MCMAKIN | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Medicare/Medicaid MMM
Medicare beneficiary access to diagnostic radiopharmaceutical testing; CMMI Proposed Accelerated Approval Payment Policy; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation, Medicare Part D and Medicare Part B issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| BRITTANY JOHNSON HERNANDEZ | — |
| MATHEW LAPINSKI | — |
| BEN LEE MCMAKIN | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.